OurGLP1 archive
Page 2 of carefully sourced research, regulatory, safety and availability reporting.
Latest GLP-1 news14 August 2026
A peer-reviewed Phase 2b trial reported up to 12.1% average weight loss with daily aleniglipron at 36 weeks. We examine the design, tolerability and why Phase 3 evidence is still needed.
Read the sourced summary13 August 2026
Blood samples from 2,970 older SELECT participants produced a more favourable proteomic dementia-risk score with semaglutide. We explain why that is intriguing but not evidence of prevention.
Read the sourced summary12 August 2026
A US Veterans Affairs Phase 3 trial plans to enrol 622 veterans across 19 currently listed sites. We explain what it will measure, why earlier trials are encouraging and what remains unknown.
Read the sourced summary11 August 2026
A 2026 multicentre study reported 16.6% average weight loss with tirzepatide and 13.4% with semaglutide at 12 months. We examine the findings, the side-effect figures and the limits of real-world evidence.
Read the sourced summary10 August 2026
The FDA has received hundreds of reports associated with compounded semaglutide and tirzepatide, while UK regulators are tackling fake pens and illegal manufacturing. Here is what each category means and what the figures cannot prove.
Read the sourced summary9 August 2026
A UK headline reported more than 150 deaths after GLP-1 drug use. We checked the MHRA Yellow Card profiles and found important distinctions between reports, reactions, fatal outcomes and proved causation.
Read the sourced summary8 August 2026
The MHRA has strengthened pancreatitis warnings for GLP-1 and dual GIP/GLP-1 medicines after 1,296 UK Yellow Card reports. Here is what the figures show, what they cannot establish and which symptoms require urgent attention.
Read the sourced summary7 August 2026
Wegovy tablets and Foundayo are both oral weight-management medicines, but their ingredients and routines differ. We explain how pills, injections, multi-agonists and new indications are creating a more complex treatment ecosystem.
Read the sourced summary6 August 2026
A 157,880-person study linked GLP-1 use with a lower rate of age-related macular degeneration. We examine the result, conflicting evidence and the difference between association and prevention.
Read the sourced summary5 August 2026
We verify the oral GLP-1 shift and compare four closely watched successors without treating company topline results, cross-trial percentages or Phase 3 status as proof of superiority.
Read the sourced summary4 August 2026
‘Whole-body medicine’ is useful industry shorthand, not a medical category. We rank the evidence across cardiovascular disease, MASH, kidney disease, asthma, addiction and Alzheimer’s.
Read the sourced summary4 August 2026
We separate Novo Nordisk’s approved oral Wegovy launch from its investigational zenagamtide programme and explain why changing treatment formats makes accurate medication history more valuable.
Read the sourced summary